Qualification and verification of protein biomarker candidates

Yingxin Zhao, Allan R. Brasier

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Scopus citations

Abstract

The importance of biomarkers has long been recognized by the public, scientific community, and industry. Yet despite extensive efforts and funding investments in biomarker discovery, only 109 protein biomarkers in plasma or serum were approved by the US Food and Drug Administration throughout 2008 (Anderson NL. Clin Chem 56:177–185, 2010), and even fewer protein biomarkers are currently used routinely in the clinic. In recent years, the introduction of new protein biomarkers approved by the US Food and Drug Administration has fallen to an average of 1.5 per year (a median of only 1 per year) (Anderson NL. Clin Chem 56:177–185, 2010). The low efficiency of biomarker development is due to several reasons, including the poor quality of clinical samples, the gap between subjective clinical definition of a disease and objective protein measurements, and high false discovery rate of differentially expressed proteins identified in the initial discovery phase (Rifai N, Gillette MA, Carr SA. Nat Biotechnol 24:971–983, 2006). It has become clear that the vast majority of differentially expressed proteins identified in the discovery phase will ultimately fail as useful clinical biomarkers, and only few true positive candidates can move through the biomarker development pipeline. Isolation of true biomarkers from the large pool of differentially expressed proteins identified in the discovery phase becomes the greatest challenge and the bottleneck in most biomarker pipelines. To succeed, after the initial discovery study (see Chap. 20), the authenticity of biomarker candidates need to be tested in a pilot study with high throughput, high accuracy and reasonable cost. This essential process is addressed by qualification and verification phase of the biomarker development pipeline.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages493-514
Number of pages22
Volume919
DOIs
StatePublished - 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume919
ISSN (Print)00652598
ISSN (Electronic)22148019

Keywords

  • Accurate inclusion mass screening (AIMS)
  • Biomarker verification
  • Cohort selection
  • Data-independent MS/MS acquisition (DIA-MS/MS)
  • ELISA-based verification
  • Parallel reaction monitoring (PRM)
  • Selected reaction monitoring (SRM)

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Qualification and verification of protein biomarker candidates'. Together they form a unique fingerprint.

  • Cite this

    Zhao, Y., & Brasier, A. R. (2016). Qualification and verification of protein biomarker candidates. In Advances in Experimental Medicine and Biology (Vol. 919, pp. 493-514). (Advances in Experimental Medicine and Biology; Vol. 919). Springer New York LLC. https://doi.org/10.1007/978-3-319-41448-5_23